Piper Sandler Maintains Overweight on Veracyte, Lowers Price Target to $54

Benzinga Newsdesk www.benzinga.com Negative 80.5%

Neg 80.5% Neu 0% Pos 0%

Piper Sandler analyst David Westenberg maintains Veracyte (NASDAQ:VCYT) with a Overweight and lowers the price target from $66 to $54.